Anti-Wuhan pneumonia like “throwing a pneumonia”? Brazil test data: China’s Kexing vaccine overall efficacy is only 50.38% | International | Newtalk Newtalk

The global epidemic of Wuhan pneumonia has not slowed down and countries have accelerated the pace of ordering and delivery of vaccines. Except for Pfizer and Moderna, which are used by most countries, Chinese-developed vaccines are also rushing to hit the market, but their safety and efficacy are still available. Disputed. On the 12th, Brazilian researchers announced the overall efficacy data of the Wuhan pneumonia vaccine developed by China Beijing Kexing Biological Products Co., Ltd., which was only 50.38%. Ricardo Palacios, director of clinical research at Instituto Butantan, Brazil’s biological research center responsible for clinical trials of the Coxing vaccine, noted that the new data includes cases of “very mild disease” that do not require clinical care. Or cases of asymptomatic infection.

On the 7th, Brazilian researchers celebrated that the Coxing vaccine has 78% protection against mild cases and called it “clinical efficacy.” However, experts and regulatory agencies criticized the lack of complete data and demanded greater transparency. In addition, Turkey, which buys the Kexing vaccine, announced data from the interim analysis of clinical trials last month, stating that the vaccine has an effective rate of 91.25%. In Indonesia, which just approved the emergency use of the Kexing vaccine, interim data from clinical trials shows that the effective rate is 65%. However, the Butantin Institute staff stated that the Brazilian clinical trial design focuses on first-line health workers during the pandemic outbreak in Brazil, including older volunteers, so it cannot be directly compared to other trials. or vaccines.

In an interview with UOL, Dimas Covas, director of the Butantin Institute, said that in addition to the “clinical utility rate”, continuous analysis also produces a new “overall utility rate.” The full data will be released at a scientific conference this week. Prior to this, Butantan Institute researchers had delayed the release of Kexing vaccine clinical trial data three times, and the institute blamed the “confidentiality clause” in the contract signed with Kexing. However, the Brazilian news portal UOL reported on the 11th that the “global effectiveness” of the Coxing vaccine was less than 60%, only 50.38%.

The effectiveness of the vaccine (efficacy) means that in an experimental setting, people who have been vaccinated are compared to those who have not been vaccinated, and those who have been vaccinated reduce the percentage of infection. For example, the phase III clinical study of the Pfizer-BioNTech vaccine indicates that the vaccine has Efficiency is 95%, that is, compared to those who have not been vaccinated, the probability of contagion of those who have been vaccinated it is reduced by 95%. The Wuhan pneumonia vaccine from Chinese National Medicine, which uses the same inactivated vaccine technology as Kexing, has an effective rate of 86%, which is lower than that of the Pfizer-BioNTech vaccine.

Brazilian President Jair Bolsonaro has repeatedly questioned the Chinese vaccine, saying that its “effectiveness appears to be very low.” The São Paulo state health minister (Jean Gorinchteyn), who buys the Chinese vaccine, is expected to also confirm that the effectiveness of the vaccine is only 50% to 90% protective after human trials. The Wall Street Post reported last month that those involved in the development of the Kexing vaccine revealed that the third phase of clinical trials of the Kexing vaccine in Brazil exceeded the threshold of more than 50%. Regulators are expected to approve the vaccine. However, experts bluntly say that a vaccine with an effective rate of more than 50% means “said not said”, because “below 50% is not qualified, and the investigation has already stopped”, and WHO will not give recognition.